# Tempus xT CDx

Source: https://onco.cc/drugs/tempus-xt-cdx/  
OnCo record `tempus-xt-cdx` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Tempus's tumour-and-normal gene panel, FDA-approved in 2023 as a companion test for EGFR antibodies in bowel cancer.

## Summary

The FDA approved Tempus xT CDx in 2023 as a 648-gene tumour-normal panel with a companion diagnostic claim for KRAS and NRAS wild-type colorectal cancer (cetuximab and panitumumab eligibility) and with tumour-profiling claims across solid tumours. The matched-normal design distinguishes inherited variants from tumour-acquired ones and reduces false positives. Tempus pairs the test with its multimodal database and trial-matching software, which is the company's commercial thesis: the test is the entry point to data.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-10
- Tags: test
- Brand: xT CDx
- Modality: Tissue NGS companion diagnostic test (648 genes, tumour-normal)
- Mechanism: Hybrid-capture sequencing of 648 genes in tumour tissue with matched normal blood or saliva to separate somatic from germline variants; reports MSI status and companion claims.
- Approvals: US 2023: Companion diagnostic for cetuximab and panitumumab (KRAS/NRAS wild-type colorectal cancer) with tumour-profiling claims

## Notes

- What a result means: a RAS mutation rules out EGFR antibodies in bowel cancer; other findings feed treatment and trial options.

## Sources

- Tempus: xT CDx: https://www.tempus.com/oncology/genomic-profiling/xt-cdx/

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Companion diagnostics](https://onco.cc/technologies/companion-diagnostic/), [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/)
- targets: [EGFR](https://onco.cc/targets/egfr/), [KRAS](https://onco.cc/targets/kras/), [NRAS](https://onco.cc/targets/nras/)
- drugs: [Cetuximab](https://onco.cc/drugs/cetuximab/), [Panitumumab](https://onco.cc/drugs/panitumumab/)
- companies: [Tempus AI](https://onco.cc/companies/tempus/)
- terms: [Germline vs somatic mutations](https://onco.cc/terms/germline-vs-somatic/), [Next-generation sequencing (NGS)](https://onco.cc/terms/ngs/)
- key papers: [Molecular biomarkers for the evaluation of colorectal cancer: guideline from ASCP, CAP, AMP and ASCO](https://onco.cc/key-papers/paper-sepulveda-molecular-biomarkers-colorectal-guideline-jco-2017/)
- biomarkers: [RAS wild-type (extended KRAS and NRAS testing)](https://onco.cc/biomarkers/ras-wild-type/)
- roadmaps: [Diagnostics roadmap: stains → gene panels → blood tests that decide treatment](https://onco.cc/roadmaps/diagnostics-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/tempus-xt-cdx.json